Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD5 | P21918 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11690746 | 0.77 | MAOA (0.54) | MAOAMAOBHSD17B3NOTUMSMN1; SMN2 | |
| SCHEMBL16229965 | 0.74 | HSD17B3 (0.36) | MAOAMAOBHSD17B3NOTUMALDH1A1 | |
| SCHEMBL13976110 | 0.74 | NPC1 (0.39) | MAOAMAOBHSD17B3NOTUMALDH1A1 | |
| SCHEMBL13966515 | 0.74 | HSD17B3 (0.37) | MAOAMAOBHSD17B3NOTUMALDH1A1 | |
| SCHEMBL14908527 | 0.73 | TIPARP (0.38) | SMN1; SMN2CYP1A2CYP2D6CYP2C19DRD2 | |
| SCHEMBL14908532 | 0.73 | SIGMAR1 (0.41) | — | |
| SCHEMBL11776394 | 0.71 | NOTUM (0.55) | HSD17B3NOTUMNPC1RAB9A | |
| SCHEMBL14908525 | 0.71 | TIPARP (0.38) | SMN1; SMN2CYP1A2CYP2D6CYP2C19DRD2 | |
| SCHEMBL130712 | 0.71 | MAOA (0.71) | MAOAMAOBNOTUMALDH1A1HPGD | |
| SCHEMBL14573056 | 0.71 | MAOA (0.56) | MAOAMAOBNOTUMALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3501546-A2 | CYSTEINE DRUG CONJUGATES AND USE OF SAME | Seattle Genetics, Inc. (US) | 2019-06-26 | — | — | EP | disclosed |
| EP-2928503-B1 | CONJUGATES OF AURISTATIN COMPOUNDS | MERSANA THERAPEUTICS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-2770977-B1 | NOVEL DOSAGE FORM | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-07-12 | — | — | EP | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20150314008-A1 | AURISTATIN COMPOUNDS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9139613-B2 | Macrocyclic compounds and methods for their production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-09-22 | — | — | US | disclosed |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | SEATTLE GENETICS, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | SEATTLE GENETICS, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| US-9119853-B2 | Sanglifehrin based compounds | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-09-01 | — | — | US | disclosed |
| US-20150023989-A1 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF | SEATTLE GENETICS, INC. | 2015-01-22 | — | — | US | disclosed |
| US-20140234414-A1 | Novel Dosage Form | Abliva Ab (SE) | 2014-08-21 | — | — | US | disclosed |
| US-8722629-B2 | Auristatin derivatives and use thereof | SEATTLE GENETICS, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-20130157960-A1 | NOVEL AURISTATIN DERIVATIVES AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130122024-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| WO-2013061052-A1 | NOVEL DOSAGE FORM | BIOTICA TECHNOLOGY LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | Bayer Pharma AG (DE) | 2013-04-18 | — | — | US | disclosed |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130122024-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | MDN1, EPCAM, VCAM1 | MAOA 3091/4885MAOB 2627/4885HSD17B3 4393/4885 |
| US-20140234414-A1 | Novel Dosage Form | SI, RAB10, SAMM50 | MAOA 1628/4885MAOB 2191/4885HSD17B3 3532/4885 |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | MAOA 3378/4885MAOB 2826/4885HSD17B3 3846/4885 |
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | MAOA 3378/4885MAOB 2826/4885HSD17B3 3846/4885 |
| US-20150023989-A1 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF | FGFR2, FGFR1, FGFR3 | MAOA 3094/4885MAOB 2765/4885HSD17B3 3075/4885 |
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | DDR1, IGFBP6, KDR | MAOA 3777/4885MAOB 3457/4885HSD17B3 4278/4885 |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | DDR1, IGFBP6, KDR | MAOA 3777/4885MAOB 3457/4885HSD17B3 4278/4885 |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | CDK4, CDKL4, FLT4 | MAOA 3378/4885MAOB 2826/4885HSD17B3 3846/4885 |
| US-20150314008-A1 | AURISTATIN COMPOUNDS AND CONJUGATES THEREOF | PBRM1, BRWD1, BRDT | MAOA 3996/4885MAOB 3901/4885HSD17B3 4654/4885 |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | HAVCR2, RPL35, CD4 | MAOA 2143/4885MAOB 2056/4885HSD17B3 652/4885 |
| US-20130157960-A1 | NOVEL AURISTATIN DERIVATIVES AND USE THEREOF | AURKC, AURKA, AURKB | MAOA 3035/4885MAOB 2799/4885HSD17B3 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.